Advanced Oncotherapy PLC Technological update (6608P)
September 04 2017 - 2:00AM
UK Regulatory
TIDMAVO
RNS Number : 6608P
Advanced Oncotherapy PLC
04 September 2017
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Technological update
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that it remains on schedule with the development of the
first LIGHT system, with successful integration of three key
elements of the device. The first Side Coupled Drift Tube Linac
("SCDTL") accelerating module has been integrated with the
Radiofrequency Quadrupole ("RFQ") and proton source, with
functionality of the combination and further proton acceleration
confirmed through the measurement of the proton beam through all
integrated units.
On 6 March 2017, the Company announced the acceleration of a
proton beam through the integrated proton source and RFQ, at the
maximum design-anticipated energy of 5 MeV.
The addition of the first SCDTL is significant as:
1. It is the first module in the next group of accelerating
structures i.e. the SCDTLs. This successful integration confirms
the SCDTL design concept and will facilitate the addition of
subsequent SCDTL modules.
2. The proton beam was recorded at 7.5MeV, as expected. This
achievement further validates the design, manufacturing and
integration of the LIGHT system.
3. As with the RFQ, acceleration of the proton beam at
relatively low energies is more challenging than at higher ones;
this result is, therefore, an important milestone in LIGHT's
development.
When fully integrated with the proton source and RFQ, it is
anticipated that four SCDTLs will be capable of producing a proton
beam of 37.5MeV.
Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy,
said: "All of our tests to generate and accelerate a proton beam
have been successful and this represents significant progress in
validating the capabilities of the first in the next group of
accelerating components. This is another notable achievement for
the team in Geneva and paves the way for the integration and
validation of subsequent SCDTL modules.
"We can confirm that, following these successful trials, the
Company remains on track to build a proton therapy system capable
of treating superficial tumours by the end of Q3 2018."
For further information, please contact:
www.avoplc.com
Advanced Oncotherapy Plc
Dr. Michael Sinclair, Tel: +44 20 3617 8728
Executive Chairman
Nicolas Serandour, CEO
Stockdale Securities (Nomad
& Joint Broker)
Antonio Bossi / David Tel: +44 20 7601 6100
Coaten
Stifel Nicolaus Europe
(Joint Broker)
Jonathan Senior / Ben Tel: +44 20 7710 7600
Maddison
Walbrook PR (Financial Tel: +44 20 7933 8780 or
PR & IR) avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 /
Mob: +44 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced
Oncotherapy's team "ADAM", based in Geneva, focuses on the
development of a proprietary proton accelerator called Linac Image
Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the
energy levels achieved in legacy machines but in a unit that is a
quarter of the size and between a quarter and a fifth of the cost.
This compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control which is not
achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology as well as better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLJMITMBIMBFR
(END) Dow Jones Newswires
September 04, 2017 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024